CJC 1295 and Ipamorelin Peptide Stack

Certificate of Analysis

Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.

Ipamorelin

• Purity: 99.74%
• Date: 03/31/2025

CJC-1295 DAC

• Purity: 98.96%
• Date: 07/03/2025

View all COAs at the bottom of this tab.

CJC 1295 DAC Data

• Purity: Our CJC-1295 DAC Peptide is produced to the highest standards of purity, ensuring accurate and reliable research results.
• Form: We provide lyophilized powder for easy handling and extended shelf life.
• Solubility: Highly soluble in water, allowing for convenient preparation of research solutions.
• Storage: Store the peptide in a cool, dry place, away from light, for extended stability. Refrigerate after reconstitution.
• CAS Number: 863288-34-0
• Molecular Weight: 3647.28 g/mol
• Class: Peptide
• Formula:  C₁₅₂H₂₅₂N₄₄O₄₂
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala- Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys

About Our CJC-1295 DAC Product

• Lyophilized sample in a sterile glass vial
• 5 mg CJC-1295 DAC per vial
• >98% purity for each sample
• Lab supplies and dilution solutions are not included

Ipamorelin Data

• Purity: Our Ipamorelin Peptide is produced to the highest standards of purity, ensuring accurate and reliable research results.
• Form: We provide lyophilized powder for easy handling and extended shelf life.
• Solubility: Highly soluble in water, allowing for convenient preparation of research solutions.
• Storage: Store the peptide in a cool, dry place, away from light, for extended stability. Refrigerate after reconstitution.
• CAS Number: 170851-70-4
• Molecular Weight: 711.86 g/mol
• Class: Polypeptide
• Formula: C₃₈H₄₉N₉O₅
• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2

About Our Ipamorelin Peptide Product

• Lyophilized sample in a sterile glass vial
• 5mg Ipamorelin per vial
• >99% purity for each sample
• Lab supplies and dilution solution are not included

Scientific Research & References

1. Timms, M., Ganio, K., Forbes, G., Bailey, S., & Steel, R. (2019). An immuno polymerase chain reaction screen for the detection of CJC‐1295 and other growth‐hormone‐releasing hormone analogs in equine plasma. Drug testing and analysis, 11(6), 804-812

2. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.

3. Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.

4. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.

5. Pinyot, A., Nikolovski, Z., Bosch, J., Such-Sanmartín, G., Kageyama, S., Segura, J., & Gutiérrez-Gallego, R. (2012). Growth hormone secretagogues: out of competition. Analytical and bioanalytical chemistry, 402, 1101-1108.

6. Campbell, R. M., Bongers, J., & Felix, A. M. (1995). Rational design, synthesis, and biological evaluation of novel growth hormone-releasing factor analogues. Biopolymers: Original Research on Biomolecules, 37(2), 67-88.

7. Campbell, R. M., Stricker, P., Miller, R., Bongers, J., Liu, W., Lambros, T., … & Heimer, E. P. (1994). Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides, 15(3), 489-495.

8. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi: 10.1210/jc. 2005-1536.

9. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.

10. Ma, X., Lin, L., Yue, J., Pradhan, G., Qin, G., Minze, L. J., … & Sun, Y. (2013). Ghrelin receptor regulates HFCS-induced adipose inflammation and insulin resistance. Nutrition & diabetes, 3(12), e99-e99.

11. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective GH secretagogue. European Journal of Endocrinology. 1998 Oct;139(5):552-61. doi: 10.1530/eje.0.1390552.

12. Johansen, P. B., Nowak, J., Skjærbæk, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Ørskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.

13. Vahl, N., Juul, A., Jørgensen, J. O., Ørskov, H., Skakkebæk, N. E., & Christiansen, J. S. (2000). Continuation of GH replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. The Journal of Clinical Endocrinology & Metabolism, 85(5), 1874-1881.

14. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., … & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of GH secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149.

15. Horvath, T. L., Castañeda, T., Tang-Christensen, M., Pagotto, U., & Tschop, M. H. (2003). Ghrelin as a potential anti-obesity target. Current Pharmaceutical Design, 9(17), 1383-1395.

16. Sjögren, K., Jansson, J. O., Isaksson, O. G., & Ohlsson, C. (2002). A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I. Endocrine, 19, 249-256.

17. D’Agostino, P. IGF-1 LR3: The rapid-acting GH alternative.

18. Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25-37.

19. Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters, 25(6), 403-406.

20. Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272.

Please note that the above references provide evidence for the potential benefits of CJC 1295 DAC Peptide and Ipamorelin peptide as stated in the product description. For more in-depth information, kindly refer to these scholarly works.